Rosetta Genomics (ROSG) Pops on New Patent for Liver Cancer
Tweet
Share
E-mailGet Alerts ROSG Hot Sheet
Join SI Premium – FREE
Rosetta Genomics, Ltd. (Nasdaq: ROSG) is surging higher following news of a new patent for targeting microRNAs for the treatment of liver cancer. Shares are up 8.8 percent.
Link
Link
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- Solowin Holdings marks 10 years, expands into stablecoins and AI
Create E-mail Alert Related Categories
Corporate News, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
